We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Endo (ENDP) Obtains FDA Approval for Cellulite Treatment
Read MoreHide Full Article
Endo International plc announced that it obtained FDA approval of collagenase clostridium histolyticum-aaes for the treatment of moderate to severe cellulite in the buttocks of adult women under the brand name, Qwo.
Per the company, Qwo is the first FDA-approved injectable treatment for cellulite.
Qwo is expected to be available throughout the United States at aesthetic healthcare practitioners’ offices starting spring 2021.
Cellulite is a localized alteration in the contour of the skin that has been reported in more than 90% of post-pubertal females and affects women of all races and ethnicities. Per the company, when injected into the treatment area, QWO releases the fibrous septae enzymatically by specifically targeting types 1 and 3 collagens. This, in turn, is expected to result in smoothing of the skin and an improved appearance of cellulite.
The approval will provide Endo with an additional source of revenue, given the wide market potential. Shares are up in pre-market trading on the news.
However, shares of Endo have lost 21.1% in the year so far compared with the industry’s 4.5% decline.
Endo’s efforts to revive its business are encouraging after its generics business plummeted due to product discontinuances and pricing pressure from increased competition. We note the company’s major competitors in this space include Mylan , Teva (TEVA - Free Report) and Novartis’ (NVS - Free Report) Sandoz.
Nevertheless, Xiaflex’s performance has been solid on higher demand in both Peyronie's disease and Dupuytren's contracture. The Sterile Injectables segment continues to gain traction as well, driven by continued strong growth in Vasostrict and Adrenalin.
Concurrent with the first-quarter results, Endo withdrew its revenue guidance due to uncertainties regarding the continued impact of the COVID-19 pandemic. Hence, second-quarter results are expected to be weak.
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This young company’s gigantic growth was hidden by low-volume trading, then cut short by the coronavirus. But its digital products stand out in a region where the internet economy has tripled since 2015 and looks to triple again by 2025.
Its stock price is already starting to resume its upward arc. The sky’s the limit! And the earlier you get in, the greater your potential gain.
Image: Bigstock
Endo (ENDP) Obtains FDA Approval for Cellulite Treatment
Endo International plc announced that it obtained FDA approval of collagenase clostridium histolyticum-aaes for the treatment of moderate to severe cellulite in the buttocks of adult women under the brand name, Qwo.
Per the company, Qwo is the first FDA-approved injectable treatment for cellulite.
Qwo is expected to be available throughout the United States at aesthetic healthcare practitioners’ offices starting spring 2021.
Cellulite is a localized alteration in the contour of the skin that has been reported in more than 90% of post-pubertal females and affects women of all races and ethnicities. Per the company, when injected into the treatment area, QWO releases the fibrous septae enzymatically by specifically targeting types 1 and 3 collagens. This, in turn, is expected to result in smoothing of the skin and an improved appearance of cellulite.
The approval will provide Endo with an additional source of revenue, given the wide market potential. Shares are up in pre-market trading on the news.
However, shares of Endo have lost 21.1% in the year so far compared with the industry’s 4.5% decline.
Endo’s efforts to revive its business are encouraging after its generics business plummeted due to product discontinuances and pricing pressure from increased competition. We note the company’s major competitors in this space include Mylan , Teva (TEVA - Free Report) and Novartis’ (NVS - Free Report) Sandoz.
Nevertheless, Xiaflex’s performance has been solid on higher demand in both Peyronie's disease and Dupuytren's contracture. The Sterile Injectables segment continues to gain traction as well, driven by continued strong growth in Vasostrict and Adrenalin.
Concurrent with the first-quarter results, Endo withdrew its revenue guidance due to uncertainties regarding the continued impact of the COVID-19 pandemic. Hence, second-quarter results are expected to be weak.
Endo currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This young company’s gigantic growth was hidden by low-volume trading, then cut short by the coronavirus. But its digital products stand out in a region where the internet economy has tripled since 2015 and looks to triple again by 2025.
Its stock price is already starting to resume its upward arc. The sky’s the limit! And the earlier you get in, the greater your potential gain.
Click Here, See It Free >>